Skip to main content

Table 7 Co-expression of FN and αvβ3 and osteosarcoma patient survival based on multivariate analysis

From: Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma

Characteristics Comparison Disease-free survival (months) Overall survival (months)
HR 95%CI P value HR 95%CI P value
FN+/αvβ3+ vs. othersa 2.66 1.13–6.23 0.025 3.75 1.36–10.36 0.011
 Tumor size (cm) < 5 vs. ≥ 5 2.55 1.06–6.14 0.036 2.57 0.72–9.24 0.147
 Enneking staging I-IIA vs. IIB 3.34 1.20–9.28 0.021 2.90 0.60–13.87 0.184
 Response to chemotherapy Good vs. poor 0.75 0.30–1.84 0.526 0.48 0.12–1.99 0.309
C-index (95%CI)   0.75 0.65–0.86   0.84 0.70–0.97  
FN+/αvβ3+ vs. FN/αvβ3 5.62 1.91–16.52 0.002 6.35 1.54–26.14 0.010
FN+/αvβ3 plus FN/αvβ3+ vs. FN/αvβ3 3.79 1.50–9.54 0.005 2.31 0.59–8.96 0.228
 Tumor size (cm) < 5 vs. ≥ 5 2.04 0.84–4.93 0.115 2.39 0.67–8.56 0.182
 Enneking staging I-IIA vs. IIB 3.46 1.22–9.77 0.019 2.69 0.55–13.08 0.220
 Response to chemotherapy Good vs. poor 1.08 0.41–2.79 0.882 0.62 0.14–2.80 0.536
C-index (95%CI)   0.79 0.69–0.90   0.85 0.71–0.98  
  1. HR hazard ratio, CI confidence interval
  2. +High expression; low/negative expression; aFN+/αvβ3 plus FN/αvβ3+ plus FN/αvβ3